Showing 3 posts of 3 posts found.

Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

October 11, 2019
Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …


NICE reject Clovis Oncology’s ovarian cancer drug Rubraca

August 6, 2019
Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma

Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …


Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show

April 3, 2019
Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma

At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …

Latest content